Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8
Benzinga Newsdesk 2 months ago
NewsDowngradesAnalyst RatingsPrice Target
Canaccord Genuity analyst Richard Close downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $3 to $1.8.
Canaccord Genuity analyst Richard Close downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $3 to $1.8.